Prosecution Insights
Last updated: July 17, 2026
Application No. 18/701,121

PURIFIED PRODUCT OF CITRUS OIL AND PRODUCTION METHOD OF PURIFIED PRODUCT OF CITRUS OIL

Non-Final OA §103§112
Filed
Apr 12, 2024
Priority
Oct 13, 2021 — JP 2021-168177 +1 more
Examiner
ROBERTS, LEZAH
Art Unit
1612
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
TAKASAGO INTERNATIONAL Corporation
OA Round
1 (Non-Final)
49%
Grant Probability
Moderate
1-2
OA Rounds
1y 10m
Est. Remaining
85%
With Interview

Examiner Intelligence

Grants 49% of resolved cases
49%
Career Allowance Rate
373 granted / 764 resolved
-11.2% vs TC avg
Strong +36% interview lift
Without
With
+35.8%
Interview Lift
resolved cases with interview
Typical timeline
4y 1m
Avg Prosecution
51 currently pending
Career history
838
Total Applications
across all art units

Statute-Specific Performance

§101
0.1%
-39.9% vs TC avg
§103
77.9%
+37.9% vs TC avg
§102
3.9%
-36.1% vs TC avg
§112
2.1%
-37.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 764 resolved cases

Office Action

§103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Response to Election/Restrictions Applicant’s election without traverse of Group IV in the reply filed on May 11, 2026 is acknowledged. Claims 1-7 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on May 11, 2026. Claims Claim Objections Claims 8-10 are objected to because of the following informalities: the claims do not appear to be completely written in black ink, making the claims difficult to read. Appropriate correction is required. Claim Rejections - 35 USC § 112 - Indefiniteness The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 8-10 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. The claims are dependent on a withdrawn claim. Therefore it is not clear what limitations are included in the claims making the claims indefinite. Claims 8-10 recites the limitation "the purified product of a citrus oil" in line 1. There is insufficient antecedent basis for this limitation in the claim. In order to advance prosecution, it will be assumed the citrus oil is derived form a citrus peel/or citrus oil in general. Claim Rejections - 35 USC § 103 - Obviousness The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. 1) Claims 8-9 are rejected under 35 U.S.C. 103 as being unpatentable over Carlson et al. (US 20070237844). Carlson et al. disclose method for removing a contaminant form an essential oil comprising contacting the essential oil including the contaminant with an aqueous alkaline solution (Abstract). The essential oils are volatile oils derived from fruit peels, leaves, stems, flowers, bark, roots, or twigs of plants, and usually carry the odor or flavor of the plant or its fruit. Essential oils include peel oils such as citrus oil. Citrus oils are derived from squeezing or pressing citrus fruit peel. Citrus oils can be derived from lemons, oranges, limes, grapefruits, tangerines, mandarins, bitter oranges, and bergamots. The alkaline solution is made with 5% sodium hydroxide, meeting strong base. An essential oil comprising 105.81 grams of cold-pressed orange oil included carbaryl at 15.51 PPM. The orange oil was contacted with 5.57 grams of an aqueous alkaline solution comprising a 5% w/w sodium hydroxide solution in an Erlenmeyer flask containing a magnetic stirring bar. The ratio of oil to NaOH solution is 19:1. The range of oil to solution may range from 1:1 to 50:1 (paragraph 0015). The oil would meet raw material because a contaminant was removed by using the sodium hydroxide solution. Therefore, it would have been obvious to have treated a raw citrus oil with sodium hydroxide to remove unwanted contaminants. It is well-settled, however, that even a slight overlap in range establishes a prima facie case of obviousness. See MPEP 2144.05. The ratio of oil to NaOH solution is 19:1. The range of oil to alkaline solution may range from 1:1 to 50:1. The amount of sodium hydroxide that would be used with 1000 g of oil based on the example would be about 0.06 mol. This is close to 0.05. Therefore, when the ratio is more than 19 in regards to the oil, the amount of alkaline substance would meet the limitation of 0.05 mol or less. Accordingly, since an overlap plainly exists here, it would have been obvious to have selected values within the overlap, consistent with the reasoning of the of MPEP 2144.05. 2) Claims 8 and 10 are rejected under 35 U.S.C. 103 as being unpatentable over Olansky et al. (US 20060286134). Olansky et al. disclose a method for removing a contaminant from an essential oil comprising contacting the essential oil including the contaminant with a strong base anion exchange resin (Abstract). Essential oils include citrus oil (paragraph 0010). Olansky et al. differ from the instant claims insofar as it does not disclose the amount of anion exchange resin. However, the resin is a result effective variable and would determine how much oil may be treated and how much contaminant can be removed. Therefore, it would have taken no more than the routine optimization to adjust the amount of resin to obtain the desired purity. See MPEP 2144.05. Claims 8-10 are rejected. Claims 1-7 are withdrawn. No claims allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to LEZAH ROBERTS whose telephone number is (571)272-1071. The examiner can normally be reached Monday-Friday 11:00-7:30. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Sahana Kaup can be reached at 571-272-6897. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /LEZAH ROBERTS/Primary Examiner, Art Unit 1612
Read full office action

Prosecution Timeline

Apr 12, 2024
Application Filed
Jun 03, 2026
Non-Final Rejection mailed — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12661309
PREPARATION AND EFFICACY OF TOOTH WHITENING TABLET INCLUDING SHMP
5y 0m to grant Granted Jun 23, 2026
Patent 12594229
Personal Care Compositions and Methods for the Same
5y 2m to grant Granted Apr 07, 2026
Patent 12594241
TOPIRAMATE ORAL LIQUID SUSPENSION AND USE THEREOF
2y 7m to grant Granted Apr 07, 2026
Patent 12582583
ORAL CARE PRODUCT COMPRISING AN ORAL CARE RHEOLOGICAL SOLID COMPOSITION
4y 11m to grant Granted Mar 24, 2026
Patent 12558387
MULTI-VIRUS ANTI-INFECTIVITY AND PRO-IMMUNITY ASSEMBLY
2y 2m to grant Granted Feb 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
49%
Grant Probability
85%
With Interview (+35.8%)
4y 1m (~1y 10m remaining)
Median Time to Grant
Low
PTA Risk
Based on 764 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month